<p class="title">Covid-19 has been a bane to many patients and their families, but nothing short of a huge boon to pharma companies.</p>.<p class="bodytext">The pandemic, which is now in its third year, has boosted the prospects of pharma industry goliaths and their smaller rivals alike, a closer look at their moving annual turnover (MAT) numbers showed by AWACS Pharmasofttech Pvt. Ltd’s data.</p>.<p class="bodytext">While big-wigs such as Sun Pharma, Zydus Cadila and Cipla gained by selling Covid-related drugs, smaller companies such as Aristo Pharmaceuticals and Alkem Laboratories benefitted from strong demand for immunity boosters and gastrointestinal medicines, analysts said.</p>.<p class="bodytext"><strong>Also Read | <a href="https://www.deccanherald.com/national/north-and-central/delhi-hospitals-stare-at-workforce-crisis-as-doctors-test-covid-positive-1067933.html">Delhi hospitals stare at workforce crisis as doctors test Covid positive </a></strong></p>.<p class="bodytext">“Alkem and Aristo did not launch any direct Covid drug but were into the allied drugs space which benefitted them,” Adbulkader Puranwala, VicePresident at Elara Capital, said.</p>.<p class="bodytext">“Zincovit (which helps to prevent vitamin and zinc deficiencies) has become a Rs 650 crore brand during Covid but prior to Covid, it was a Rs 200 crore brand. Even for Alkem, their Vitamin brand A to Z was a Rs 150 crore brand which turned out to be Rs 260 crore brand during the pandemic,” Puranwala pointed out.</p>.<p class="bodytext">Covid-19 was initially considered a respiratory disease, but the virus behind it can cause other issues in the human body and affect major organs including those that aid in digestion.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/north-and-central/delhi-govt-tells-private-hospitals-to-reserve-at-least-40-of-beds-for-covid-patients-1067924.html" target="_blank">Delhi govt tells private hospitals to reserve at least 40% of beds for Covid patients</a></strong></p>.<p class="bodytext">“Covid is definitely becoming a chronic disease and there is definitely a market, but in the long run, companies that look at the margin will benefit. There is a sizable opportunity in Covid which is why all these companies are benefitting,” said Amit Khurana, Head of Equities and Research at Dolat Capital.</p>.<p class="bodytext">Aristo, Alkem, Abbott, Sun Pharma, Cipla, Macleods all figure in the list of the top 10 companies in the Covid and Covid-related space, as per AWACS Pharmasofttech Pvt. Ltd’s MAT numbers.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>
<p class="title">Covid-19 has been a bane to many patients and their families, but nothing short of a huge boon to pharma companies.</p>.<p class="bodytext">The pandemic, which is now in its third year, has boosted the prospects of pharma industry goliaths and their smaller rivals alike, a closer look at their moving annual turnover (MAT) numbers showed by AWACS Pharmasofttech Pvt. Ltd’s data.</p>.<p class="bodytext">While big-wigs such as Sun Pharma, Zydus Cadila and Cipla gained by selling Covid-related drugs, smaller companies such as Aristo Pharmaceuticals and Alkem Laboratories benefitted from strong demand for immunity boosters and gastrointestinal medicines, analysts said.</p>.<p class="bodytext"><strong>Also Read | <a href="https://www.deccanherald.com/national/north-and-central/delhi-hospitals-stare-at-workforce-crisis-as-doctors-test-covid-positive-1067933.html">Delhi hospitals stare at workforce crisis as doctors test Covid positive </a></strong></p>.<p class="bodytext">“Alkem and Aristo did not launch any direct Covid drug but were into the allied drugs space which benefitted them,” Adbulkader Puranwala, VicePresident at Elara Capital, said.</p>.<p class="bodytext">“Zincovit (which helps to prevent vitamin and zinc deficiencies) has become a Rs 650 crore brand during Covid but prior to Covid, it was a Rs 200 crore brand. Even for Alkem, their Vitamin brand A to Z was a Rs 150 crore brand which turned out to be Rs 260 crore brand during the pandemic,” Puranwala pointed out.</p>.<p class="bodytext">Covid-19 was initially considered a respiratory disease, but the virus behind it can cause other issues in the human body and affect major organs including those that aid in digestion.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/north-and-central/delhi-govt-tells-private-hospitals-to-reserve-at-least-40-of-beds-for-covid-patients-1067924.html" target="_blank">Delhi govt tells private hospitals to reserve at least 40% of beds for Covid patients</a></strong></p>.<p class="bodytext">“Covid is definitely becoming a chronic disease and there is definitely a market, but in the long run, companies that look at the margin will benefit. There is a sizable opportunity in Covid which is why all these companies are benefitting,” said Amit Khurana, Head of Equities and Research at Dolat Capital.</p>.<p class="bodytext">Aristo, Alkem, Abbott, Sun Pharma, Cipla, Macleods all figure in the list of the top 10 companies in the Covid and Covid-related space, as per AWACS Pharmasofttech Pvt. Ltd’s MAT numbers.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>